Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: HIV-infection Clear all
Completed Phase 2 Interventional Results available

Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV

NCT02624180
View directory record Official record
Conditions
Coronary Artery Disease, Human Immunodeficiency Virus
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Early Phase 1 Interventional

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

NCT01836068
View directory record Official record
Conditions
HIV
Interventions
Enfuvirtide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

NCT03122223
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Not applicable Interventional

A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients With HIV Disease

NCT00000662
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2016 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment

NCT01818596
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
E/C/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone

NCT00000788
View directory record Official record
Conditions
Candidiasis, HIV Infections
Interventions
Methadone hydrochloride, Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

NCT01578889
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device
Biological · Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
5
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Patient Navigation Intervention for PrEP Continuum of Care Among Young Latino MSM (PrEParate)

NCT04048382
View directory record Official record
Conditions
HIV/AIDS
Interventions
Patient Navigation, Usual Care
Behavioral · Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 29 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 1 Interventional

A Phase I/II Open Label Study To Evaluate the Antiviral Potential of Combination Low-Dose Therapy With Zidovudine and Interferon-Alpha 2A in Patients With Symptomatic HIV Disease

NCT00000696
View directory record Official record
Conditions
HIV Infections
Interventions
Interferon alfa-2a, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
6
States / cities
Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Formative Study to Explore the Sensory Perceptions of Vaginal Product Users

NCT01334827
View directory record Official record
Conditions
Microbicide Delivery System Acceptability
Interventions
high volume gel, low volume gel, vaginal film
Other
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Not applicable Interventional

The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients

NCT00000861
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
1,900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1997
U.S. locations
14
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

NCT01731691
View directory record Official record
Conditions
HIV Disease
Interventions
α1 Proteinase Inhibitor, Placebos
Biological · Drug
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs in HIV-1 Infected Patients

NCT00002374
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Beverly Hills, California • Los Angeles, California • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 5:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HIV Accelerated Liver Disease in Uganda

NCT01524562
View directory record Official record
Conditions
Fibrosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
786 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced Jul 23, 2026, 5:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Computer-Generated Vs. Standard Informed Consent for HIV Research Studies

NCT00104559
View directory record Official record
Conditions
HIV Infections
Interventions
iMIC-generated consent form and tutorial, Standard paper consent form
Behavioral
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving the Reproductive Health of Families

NCT03858803
View directory record Official record
Conditions
Reproductive Health
Interventions
Families Matter 2, Living as a Safer Teen
Behavioral
Lead sponsor
Portland State University
Other
Eligibility
13 Years to 80 Years
Enrollment
945 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 23, 2026, 5:21 AM EDT
Completed No phase listed Observational Results available

Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

NCT00119405
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of a New HIV Vaccine

NCT00051922
View directory record Official record
Conditions
HIV Infections
Interventions
PolyEnv1
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 32 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 23, 2026, 5:21 AM EDT
Withdrawn Phase 2 Interventional

CBD for Sleep in People With HIV

NCT05097651
View directory record Official record
Conditions
Sleep Disturbance
Interventions
Cannabidiol oral solution, Inert sesame seed oil
Drug
Lead sponsor
Mariana Cherner, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

NCT03387462
View directory record Official record
Conditions
Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
Interventions
Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app
Drug · Other
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 3 Interventional Results available

Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1

NCT02707861
View directory record Official record
Conditions
HIV
Interventions
ibalizumab, Optimized Background Regimen
Drug
Lead sponsor
TaiMed Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
31
States / cities
Long Beach, California • Los Angeles, California • Palm Springs, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults

NCT01962961
View directory record Official record
Conditions
HIV, Endothelial Dysfunction, Oxidative Stress
Interventions
PharmaNAC (N-acetylcysteine), Matching placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 5:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Influences Transitions in Youth Health (CITY) Health II - Center for the Study of Community Health

NCT04320186
View directory record Official record
Conditions
Sexually Transmitted Diseases, HIV Infections
Interventions
Entertainment education, video
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 25 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2023 · Synced Jul 23, 2026, 5:21 AM EDT